Citigroup Has Lowered Expectations for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price target cut by investment analysts at Citigroup from $88.00 to $87.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical device company’s stock. Citigroup’s price target would indicate a potential upside of 13.65% from the company’s current price.

Several other equities research analysts also recently issued reports on COO. Rothschild & Co Redburn downgraded Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price target on the stock. in a research report on Wednesday. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $73.00 target price on shares of Cooper Companies in a report on Friday, January 9th. Robert W. Baird lifted their price target on Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, Morgan Stanley lifted their price target on Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Cooper Companies Price Performance

NASDAQ COO opened at $76.55 on Friday. Cooper Companies has a 1 year low of $61.78 and a 1 year high of $89.83. The company has a fifty day simple moving average of $82.11 and a 200 day simple moving average of $75.98. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The company has a market cap of $14.94 billion, a P/E ratio of 37.90, a P/E/G ratio of 2.19 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.03 by $0.07. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. On average, sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Insider Activity

In other Cooper Companies news, insider Holly R. Sheffield bought 1,230 shares of Cooper Companies stock in a transaction dated Tuesday, December 16th. The shares were acquired at an average cost of $80.75 per share, with a total value of $99,322.50. Following the acquisition, the insider directly owned 39,052 shares of the company’s stock, valued at $3,153,449. The trade was a 3.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Maria Rivas bought 1,000 shares of Cooper Companies stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the completion of the acquisition, the director directly owned 11,141 shares in the company, valued at $915,010.33. This represents a 9.86% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 16,014 shares of company stock valued at $1,304,416. Corporate insiders own 2.08% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors have recently bought and sold shares of the business. New York Life Investment Management LLC boosted its stake in Cooper Companies by 0.6% in the fourth quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock worth $2,241,000 after purchasing an additional 158 shares in the last quarter. Root Financial Partners LLC increased its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Cooper Companies by 14.1% in the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock valued at $111,000 after buying an additional 167 shares during the last quarter. Wealth Alliance LLC raised its holdings in shares of Cooper Companies by 4.2% in the second quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after buying an additional 171 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. lifted its position in Cooper Companies by 1.3% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock worth $961,000 after buying an additional 175 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.